Myasthenia Gravis Treatment Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis By 2027 Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease which causes weakness in skeletal muscles in the arms and legs. Double vision, facial paralysis, difficulty in walking, dropping of eyelids, are symptoms of myasthenia gravis. This disease is diagnosed by tests such as repetitive nerve stimulation test, blood test for antibodies, edrophonium test, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI). Corticosteroids drugs (azathioprine, and cyclosporine) and Acetylcholine esterase inhibitors (Edrophonium, and Pyridostigmine) are used for the treatment of MG. Get In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2625 Myasthenia Gravis Treatment Market - Drivers Consistent research and development activities are expected to propel growth of the myasthenia gravis treatment market. For instance, in October 2017, Alexion Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for Soliris which contains eculizumab as an active component. This drug is used for treatment of antibody positive generalized myasthenia gravis, and it is also used in treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS). Increasing number of clinical trials for treatment of myasthenia gravis are expected to drive the myasthenia gravis treatment market growth. For instance, in December 2017, Novartis AG initiated phase II clinical trial of CFZ533 for treatment of severe myasthenia gravis. The main function of CFZ533 is the modification of immune response by deactivation of white blood cells. Hence, it is expected to help with improvement and management of severe myasthenia gravis. Myasthenia Gravis Treatment Market - Regional Analysis On the basis of region, the global myasthenia gravis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the myasthenia gravis treatment market over the forecast period. This is owing to increasing incidence and prevalence of myasthenia gravis in the U.S. For instance, in October 2018, according to the National Center for Biotechnology Information (NCBI), incidence of myasthenia gravis was around 5 to 30 cases per million person years and prevalence is around 10 to 20 cases per 100,000 population in U.S. Report includes chapters which deeply display the following deliverable about industry : • Myasthenia Gravis Treatment Market Research Objective and Assumption • Myasthenia Gravis Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Myasthenia Gravis Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Myasthenia Gravis Treatment Market, By Regions • Myasthenia Gravis Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Myasthenia Gravis Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Myasthenia Gravis Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Myasthenia Gravis Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Myasthenia Gravis Treatment Market - Competitive Analysis Key players operating in the myasthenia gravis treatment market are Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceutical International, Inc. Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Shire plc, and Avadel Pharmaceutical, PLC. Myasthenia Gravis Treatment Market – Taxonomy By Medications • Cholinesterase Inhibitors • Corticosteroids • Immunosuppressants • Plasmapheresis • Intravenous immunoglobulin (IVIg) • Monoclonal Antibody By Distribution Channels • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/myasthenia-gravis-treatment-market2625 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Myasthenia gravis (MG) is a type of chronic autoimmune neuromuscular disease which causes weakness in skeletal muscles in the arms and legs.
© Copyright 2024 Paperzz
